Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 in Recurrent Extensive Stage Small Cell Lung Cancer
NCT00773955Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2008
- Primary completion
- Oct 2009
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of r-(-)-gossypol acetic acid in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Started Nov 2008; status: completed.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00773955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00773955.